PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Disease Reportslymphoid leukemia
MeSH D007945 - lymphoid leukemia
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
See list view
D008232:Lymphoproliferative disorders
2 Companies
2 Drugs
$
Success rate
D007938:Leukemia
131 Companies
21 Drugs
$
Success rate
D007945: 
Lymphoid leukemia
46 Companies
14 Drugs
$
Success rate
D015448:B-cell leukemia
0 Companies
0 Drugs
Success rate
D015456:Biphenotypic leukemia acute
0 Companies
0 Drugs
Success rate
D015458:T-cell leukemia
11 Companies
1 Drug
$
Success rate
D015463:Prolymphocytic leukemia
0 Companies
0 Drugs
Success rate
D054198:Precursor cell lymphoblastic leukemia-lymphoma
50 Companies
20 Drugs
$
Success rate
Events Timeline
Loading
Commercial
Company Name
Drug Name
Trade Name
Patent Expires
Approval Date
Revenue
Period
TevaImatinib Imatinib  2016-08-04   
Imatinib Imatinib Teva  2013-01-07   
Imatinib Imatinib Teva B.V  2017-11-15   
Novast LaboratoriesClofarabine Clofarabine  2018-09-14   
MylanClofarabine Clofarabine  2017-11-06   
Imatinib Imatinib  2017-06-21   
Bendamustine Bendamustine  2023-04-28   
RocheObinutuzumab Gazyvaro  2014-07-22   
Rituximab MabThera  1998-06-02   
SandozRituximab Rixathon  2017-06-15   
Rituximab Riximyo  2017-06-15   
AbbVieVenetoclax Venclexta 2030-05-26 2016-04-11 $2,517 M Q4/23-Q3/24 
Venetoclax Venclyxto  2016-12-04   
NovartisOfatumumab Arzerra  2010-04-19   
Imatinib Gleevec  2001-05-10 $887 M Q2/20-Q2/23 
Imatinib Glivec  2001-11-07   
Ofatumumab Kesimpta  2009-10-26 $1,593 M Q2/21-Q2/24 
SanofiClofarabine Clolar  2004-12-28   
Clofarabine Evoltra  2006-05-29   
PfizerRituximab Ruxience  2019-07-23 $390 M Y2023 
Dr Reddys LaboratoriesBendamustine Bendamustine  2022-12-07   
Clofarabine Clofarabine  2017-11-06   
Imatinib Imatinib  2018-08-13   
1
2
3
4
5
>
Clinical Trials
Historical Success Rate
Phase 1
39%
13/33
Phase 2
10%
4/40
Phase 3
88%
15/17
Approved: 13Overall Success rate: 3%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name
Phase 1
Phase 2
Phase 3
Phase 4
Drug Name
Teva
Imatinib,
Imatinib mesylate
Roche
Rituximab,
Obinutuzumab,
Edrecolomab,
Doconexent,
Terfenadine,
Sodium lactate,
Aspartame,
Bevifimod,
Microcrystalline cellulose,
Corticoids,
Arm1,
Cc5013,
Abt199
Sandoz
Rituximab
AbbVie
Venetoclax,
Navitoclax,
Rilotumumab,
Ademetionine,
Calcium dobesilate,
Doconexent,
Sodium lactate,
Bevifimod,
Muromonab-cd3,
Microcrystalline cellulose,
Retinol,
Caelyx,
Doxorubin,
Ibi301,
Vp16,
Folinoral,
Arm1,
Hydroxydaunomycin,
Cc5013,
Cmab819,
Evidence,
Abt199,
Tqb2303
Novartis
Imatinib,
Ofatumumab,
Imatinib mesylate,
Tbo-filgrastim,
Cilmostim,
Lenograstim,
Buparlisib,
Ademetionine,
Calcium dobesilate,
Doconexent,
Regramostim,
Genistein,
Ianalumab,
Sodium lactate,
Afuresertib,
Aspartame,
Bevifimod,
LUCATUMUMAB,
SOTRASTAURIN,
Microcrystalline cellulose,
Corticoids,
Caelyx,
JBH492,
Doxorubin,
Vp16,
Solumedrol,
Triapine,
Sti571,
Arm1,
Hydroxydaunomycin,
Arm2,
Cc5013
Sanofi
Clofarabine,
Mycophenolate sodium,
Tbo-filgrastim,
Lenograstim,
Ademetionine,
Calcium dobesilate,
Terfenadine,
Sodium lactate,
ALVOCIDIB,
Aspartame,
Bevifimod,
COLTUXIMAB RAVTANSINE,
VOXTALISIB,
Microcrystalline cellulose,
Caelyx,
Doxorubin,
Allograft,
Vp16,
Sti571,
Antacid,
Arm1,
Hydroxydaunomycin,
Arm2,
Cc5013,
Evidence,
Sominex
Pfizer
Rituximab,
Salicylic acid,
Cilmostim,
Enoblituzumab,
Agatolimod,
Calcium dobesilate,
Terfenadine,
Pegargiminase,
Serine,
Sodium lactate,
Aspartame,
Bevifimod,
Quilizumab,
Microcrystalline cellulose,
Allr3,
Caelyx,
Doxorubin,
Pf03512676,
Vp16,
Pd0332991,
Solumedrol,
Sti571,
Hydroxydaunomycin,
Sominex
Apotex
Imatinib,
Imatinib mesylate
1
2
3
4
>
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use